A lung cancer diagnosis can be overwhelming. Many patients turn to a second opinion to make sense of their condition and treatment options. Now, a new initiative is encouraging them to take it one step further – by seeking a third opinion: their own.

The 3rd Opinion, the patient’s own opinion, is a new term that advocates for a shift in mindset: one where patients are supported to speak up, share what matters to them and become active partners in their care journey.

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making plays a vital role in individualizing care by integrating clinical evidence with what matters most to each individual.

Johnson & Johnson created the 3rd Opinion to help patients understand when your medical expertise aligns with what matters most to them, they get the best treatment.

In the rapidly evolving world of lung cancer, where time is of the essence, we’re here to stand with you so your patients have the confidence to make their opinion count.

Join us in empowering patients to make The 3rd Opinion their own – because the best treatment reflects your medical expertise and what matters most to them.

For more information about the patient story and the role of shared decision-making, please attend our symposium, “The First Move Matters,” at 13:45 – 14:45 on 13 September 2026 in Room 202, ASEM Ballroom, Level 2, COEX Convention & Exhibition Center.

To learn more about The 3rd Opinion, click here.

For more on how J&J is transforming the trajectory of lung cancer, click here.